Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

01 févr. 2018 08h15 HE | Source: Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Announces Allowances of Two U.S. Patent Applications

CHARLOTTESVILLE, Va., Feb. 01, 2018 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) (“Diffusion” or “the Company”), a clinical-stage biotechnology company focused on extending the...
29 janv. 2018 16h00 HE | Source: Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Announces First Patient Dosed in Phase 3 Trial with TSC in Inoperable Glioblastoma Multiforme

CHARLOTTESVILLE, Va., Jan. 29, 2018 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) (“Diffusion” or “the Company”), a clinical-stage biotechnology company focused on extending the...
24 janv. 2018 07h30 HE | Source: Diffusion Pharmaceuticals Inc.

Abstract Outlining Pre-Hospital Stroke Study with Diffusion Pharmaceuticals’ TSC To Be Presented at the International Stroke Conference

CHARLOTTESVILLE, Va., Jan. 24, 2018 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq:DFFN) (“Diffusion” or “the Company”), a clinical-stage biotechnology company focused on improving...
18 janv. 2018 06h00 HE | Source: Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Announces $12 Million Underwritten Public Offering

CHARLOTTESVILLE, Va., Jan. 18, 2018 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq:DFFN) (“Diffusion” or the “Company”), a clinical-stage biotechnology company focused on extending the...
03 janv. 2018 08h00 HE | Source: Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals to Present at the 10th Annual Biotech Showcase™ Conference

CHARLOTTESVILLE, Va., Jan. 03, 2018 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) (“Diffusion” or “the Company”), a clinical-stage biotechnology company focused on extending the...
27 déc. 2017 08h00 HE | Source: Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Begins Phase 3 Clinical Trial with TSC in Glioblastoma Multiforme

CHARLOTTESVILLE, Va., Dec. 27, 2017 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) (“Diffusion” or “the Company”), a clinical-stage biotechnology company focused on extending the...
20 nov. 2017 08h00 HE | Source: Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Regains Compliance with Nasdaq Capital Market Minimum Equity Rule

CHARLOTTESVILLE, Va., Nov. 20, 2017 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq:DFFN) (“Diffusion” or “the Company”), is a clinical-stage biotechnology company focused on extending...
13 nov. 2017 08h00 HE | Source: Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Business Update

FDA Clears Phase 3 Protocol for Patient Enrollment in GBM Brain Cancer Trial“First Patient In” Expected this YearCompany Charter Amendment Addresses Nasdaq Listing IssueAdditions to Board and...
17 oct. 2017 07h30 HE | Source: Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Receives Final FDA Protocol Guidance for Phase 3 Clinical Trial with TSC in Patients Newly Diagnosed with Inoperable Glioblastoma Multiforme

CHARLOTTESVILLE, Va., Oct. 17, 2017 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) (“Diffusion” or “the Company”), a clinical-stage biotechnology company focused on extending the...
10 oct. 2017 10h00 HE | Source: Diffusion Pharmaceuticals, Inc.

Diffusion Pharmaceuticals to Present at the 2017 BIO Investor Forum

CHARLOTTESVILLE, Va., Oct. 10, 2017 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) (“Diffusion” or “the Company”), a clinical-stage biotechnology company focused on the development...

Page précédente

Page suivante